ArticleExperimental hematology & oncology2022

A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy.

Yu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.